Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Tagworks Pharmaceuticals B V holds a company patent portfolio with 4 pending office actions. These actions are situated within the Biotechnology & Pharmaceuticals technology area. The portfolio involves 3 distinct art units and 4 distinct examiners.
The busiest examiner, SCHLIENTZ, LEAH H, is currently managing 1 pending office action. Since the busiest examiner only has 1 pending office action, it follows that all 4 pending office actions are distributed among 4 different distinct examiners. This indicates that every active matter for the company is being reviewed by a unique individual.
For practitioners, the involvement of 4 distinct examiners across 4 pending office actions means that no two cases share the same examiner. The 3 distinct art units involved suggest that the Biotechnology & Pharmaceuticals technology being patented is spread across several technical groups. Managing these 4 pending office actions requires a separate strategy for each application, as there is no examiner-level overlap to leverage across the current portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, LEAH H | 1 | 41.9% | +38.5% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| MCANANY, JOHN D | 1 | 67.2% | +43.7% |
| PERREIRA, MELISSA JEAN | 1 | 52.0% | +25.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17052928 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | PERREIRA, MELISSA JEAN | 51d overdue |
| 19400602 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | SCHLIENTZ, LEAH H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18497645 | BIO-ORTHOGONAL DRUG ACTIVATION | COLEMAN, BRENDA LIBBY | 147d overdue |
| 17052928 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | PERREIRA, MELISSA JEAN | 51d overdue |
| 19400602 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | SCHLIENTZ, LEAH H | — |
| 17619794 | TETRAZINES FOR HIGH CLICK RELEASE SPEED AND YIELD | MCANANY, JOHN D | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| 1624 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19400602 | AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO | SCHLIENTZ, LEAH H | 1618 | §103§112Other | Final Rejection | — | Pending | Nov 25, 2025 |
| 18497645 | BIO-ORTHOGONAL DRUG ACTIVATION | COLEMAN, BRENDA LIBBY | 1624 | Other | Final Rejection | 147d overdue | Pending | Oct 30, 2023 |
| 17619794 | TETRAZINES FOR HIGH CLICK RELEASE SPEED AND YIELD | MCANANY, JOHN D | 1625 | §103 | Final Rejection | — | Pending | Dec 16, 2021 |
| 17052928 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD | PERREIRA, MELISSA JEAN | 1618 | §103§112 | Non-Final OA | 51d overdue | Pending | Nov 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial